Eli Lilly's tirzepatide overtakes Keytruda as the world's top-selling drug

statnews.com

Eli Lilly's tirzepatide, used for diabetes and weight loss, has become the world's best-selling medicine, surpassing Merck's Keytruda. In the third quarter, tirzepatide generated $10.1 billion in sales, while Keytruda, a cancer drug, earned $8.1 billion. Tirzepatide achieved this status rapidly after its approvals in 2022 and 2024. This shift highlights the significant demand for GLP-1 based drugs and intense competition in the obesity market, with Eli Lilly now seen as leading over Novo Nordisk.


With a significance score of 6.2, this news ranks in the top 0.1% of today's 32359 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: